

HR 1020

Compassionate Freedom of Choice Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 13, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 17, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/1020>

Sponsor

Name: Rep. Griffith, H. Morgan [R-VA-9]

Party: Republican • State: VA • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Brat, Dave [R-VA-7]	R · VA		Feb 13, 2017

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 17, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Compassionate Freedom of Choice Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to declare that nothing in that Act or in the Public Health Service Act prevents or restricts, and the Food and Drug Administration (FDA) may not prevent or restrict, the manufacture, importation, distribution, or sale of drugs or medical devices that are intended for terminally ill patients, have been the subject of a clinical trial, and have not been approved by the FDA.

The FDA may not require the disclosure, collection, or reporting of certain information concerning such drugs or devices. The sponsor of a clinical trial may voluntarily disclose, collect, or report such information to the FDA.

Except in the case of gross negligence or willful misconduct, a person who manufactures, imports, distributes, prescribes, or administers such a drug or device is not liable under state or federal law for loss, damage, or injury from the development, testing, production, acquisition, use, safety, or effectiveness of the drug or device.

Actions Timeline

- **Feb 17, 2017:** Referred to the Subcommittee on Health.
- **Feb 13, 2017:** Introduced in House
- **Feb 13, 2017:** Referred to the House Committee on Energy and Commerce.